首页 Nevro(usNVRO)-基本信息

Nevro(usNVRO)-基本信息

日报更新时间:04-15 10:22

周报更新时间:04-11 03:39

行情信息

今开价:152.72

最高价:152.72

成交量:273620.0

昨收价:152.14

最低价:147.045

最新价:148.63

行情图标
概要信息

英文名称:Nevro


行业:医疗


简介:Nevro Corp.于2006年3月10日在明尼苏达州注册成立,该公司旨在为最初集中在慢性疼痛的治疗而生产和推广创新的治疗神经障碍主动植入式医疗设备


电话:1-650-2510005


最新量化综合结论
百科信息
  • 相关网站
  • 百科
  • 员工交易记录
  • 持股信息
  • 领导人信息

Nevro公司是一家医疗器械公司,在美国,欧洲和澳大利亚开发和商业化一个神经调节平台,用于治疗慢性疼痛。Nevro提供Senza System,一个脊髓刺激系统(Spinal Cord Stimulator,SCS),提供其专有技术的HF10 Therapy——一种先进的SCS疗法,提供脊髓每秒10 kHz的电脉冲,相比于传统SCS,其可利用介于40 Hz至60 Hz之间较低的频率刺激,亦可缓解背部及腿部疼痛的感觉异常。电脉冲是将极小电极的发电机植入于接近脊髓的皮肤底下,其可充电电池拥有至少10年的电池寿命并符合CE标准。Nevro Corp.通过其直销部门,以及销售代理和独立分销商网络销售其产品。

交易日期 交易人 职位 类型 交易份额 价格
2017-08-15 Jaeger (Wilfred E. M.D.) Director Sell 10701 84.04
2017-08-15 Jaeger (Wilfred E. M.D.) Director Sell 299 82.75
2017-08-15 Jaeger (Wilfred E. M.D.) Director Sell 236 84.04
2017-08-15 Jaeger (Wilfred E. M.D.) Director Sell 13501 82.75
2017-08-14 Jaeger (Wilfred E. M.D.) Director Sell 29024 82.54
2017-08-14 Jaeger (Wilfred E. M.D.) Director Sell 641 82.54
2017-08-13 Galligan (Andrew H) Chief Financial Officer Sell 7000 82.31
2017-08-13 Galligan (Andrew H) Chief Financial Officer Buy 652 3.60
2017-08-13 Jaeger (Wilfred E. M.D.) Director Sell 546 82.40
2017-08-13 Jaeger (Wilfred E. M.D.) Director Sell 24709 82.40
2017-08-13 Galligan (Andrew H) Chief Financial Officer Buy 6144 3.60
2017-08-13 Galligan (Andrew H) Chief Financial Officer Buy 204 18.00
2017-08-01 Christoforou (Christofer) Officer Sell 939 82.00
2017-05-31 Elghandour (Rami) Chief Executive Officer Sell 6231 69.74
2017-05-31 Elghandour (Rami) Chief Executive Officer Sell 2077 69.74
2017-05-24 DeMane (Michael F) Director Buy 1518 --
2017-05-24 Fischer (Frank M) Director Buy 1518 --
2017-05-24 Jaeger (Wilfred E. M.D.) Director Buy 1518 --
2017-05-24 McCormick (Shawn T) Director Buy 1518 --
2017-05-24 Earnhardt (Lisa D) Director Buy 1518 --
2017-05-24 Behbahani (Ali) Director Buy 1518 --
2017-05-24 Vale (Brad) Director Buy 1518 --
2017-05-14 Galligan (Andrew H) Chief Financial Officer Sell 1306 76.40
2017-05-14 Galligan (Andrew H) Chief Financial Officer Sell 2698 75.55
2017-05-14 Galligan (Andrew H) Chief Financial Officer Sell 3496 74.69
2017-05-14 Galligan (Andrew H) Chief Financial Officer Sell 2698 75.55
2017-05-08 Galligan (Andrew H) Chief Financial Officer Buy 5000 1.44
2017-05-01 DeMane (Michael F) Director Sell 16000 97.00
2017-04-30 DeMane (Michael F) Director Sell 13800 95.00
2017-04-30 Elghandour (Rami) Chief Executive Officer Sell 10000 95.03
第 页, 共 11 页 首页 上页 下页 末页

机构持股
持有者 持有份额 持股比例 份额变化 变化率 报告日期
Deerfield Management Co 579463 1.90% -334810 -36.62% 2019-03-31
OppenheimerFunds Inc 1500000 4.91% -- -- 2019-03-31
T. Rowe Price Associates, Inc. 1607828 5.27% 620562 62.86% 2019-03-31
D. E. Shaw & Co LP 1850720 6.06% 534630 40.62% 2019-03-31
ArrowMark Colorado Holdings, LLC (ArrowMark Partners) 1882009 6.17% 95486 5.34% 2019-03-31
Franklin Advisers, Inc. 2104204 6.89% 85630 4.24% 2019-03-31
Franklin Resources Inc 2123291 6.96% 86375 4.24% 2019-03-31
BlackRock Inc 2553893 8.37% -211503 -7.65% 2019-03-31
Vanguard Group Inc 2568494 8.41% -41077 -1.57% 2019-03-31
Invesco Ltd (OFI / OppenheimerFunds) 1500000 4.91% -- -- 2019-07-31
Millennium Management LLC 1110912 3.64% -30167 -2.64% 2019-03-31
BlackRock Fund Advisors 1098780 3.60% 12474 1.15% 2019-07-31
Northern Trust Investments Inc 583376 1.91% 12777 2.24% 2019-07-31
Vanguard 601301 1.97% -97156 -13.91% 2019-07-31
Broadfin Capital, LLC 622615 2.04% -121800 -16.36% 2019-03-31
Adage Capital Partners Gp LLC 700000 2.29% 592500 551.16% 2019-03-31
Partner Fund Management LP 721229 2.36% 165134 29.70% 2019-03-31
Vanguard Investments Australia Ltd 787215 2.58% 7822 1.00% 2019-07-31
State Street Corporation 815603 2.67% 54557 7.17% 2019-03-31
Fred Alger Management Inc 967176 3.17% 433655 81.28% 2019-03-31
BlackRock Asset Management Canada Ltd 679355 2.23% -207 -0.03% 2019-05-31
Geode Capital Management, LLC 617990 2.02% 335351 118.65% 2018-12-31
Bank of America Corporation 895716 2.93% 696721 350.12% 2018-12-31
OFI Global Asset Management, Inc. 1500000 4.91% -725 -0.05% 2019-04-30
Point72 Asset Management, L.P. 1318707 4.34% -171935 -11.53% 2018-12-31
Credit Suisse First Boston (CSFB) 595759 1.96% 52692 9.70% 2018-12-31
JPMorgan Chase & Co 1051674 3.46% 144359 15.91% 2018-09-30
Zevenbergen Capital Investments LLC 673480 2.22% 5750 0.86% 2018-09-30
Orbimed Advisors, LLC 1357691 4.47% 97600 7.75% 2018-09-30
Consonance Capital Management LP 1446333 4.76% 503263 53.36% 2018-09-30
Jennison Associates LLC 1501045 4.98% -189720 -11.22% 2018-09-30
HHG PLC 1241720 4.12% -643835 -34.15% 2018-09-30
Janus Capital Management LLC 910830 3.02% -386496 -29.79% 2018-12-31
BlackRock Institutional Trust Company NA 810645 2.69% 62932 8.42% 2018-06-30
Wells Fargo Funds Management LLC 898931 2.98% -105676 -10.52% 2018-11-30
PGIM Investments LLC 965810 3.20% 383 0.04% 2018-11-30
Goldman Sachs Group Inc 749756 2.49% -164415 -17.99% 2018-06-30
Wells Capital Management Inc. 1317188 4.37% 557101 73.29% 2018-06-30
AllianceBernstein L.P. 1316588 4.37% -205460 -13.50% 2018-06-30
Wells Fargo & Co 1366980 4.53% 543401 65.98% 2018-06-30
Franklin Advisers Inc 1733338 5.76% 181827 11.72% 2018-06-30
AllianceBernstein LP 1316588 4.37% -205460 -13.50% 2018-06-30
Arrowpoint Asset Management, LLC 945992 3.14% 183193 24.02% 2018-06-30
Goldman Sachs Asset Management LP 644897 2.14% -201292 -23.79% 2018-06-30
State Street Corp 645622 2.15% 61300 10.49% 2018-06-30
Invesco Advisers, Inc 611650 2.03% -7172 -1.16% 2018-06-30
Artisan Partners Limited Partnership 596939 1.98% 9152 1.56% 2018-06-30
Fidelity Management and Research Company 583000 1.94% 191000 48.72% 2018-06-30
Kornitzer Capital Management Inc 578841 1.92% -41972 -6.76% 2018-06-30
J P Morgan Asset Management (UK) Ltd 511803 1.71% 6724 1.33% 2018-03-31
Frontier Capital Management CO Inc 831786 2.78% -55616 -6.27% 2018-03-31
Prudential Investments LLC 1062264 3.54% 216605 25.61% 2018-05-31
Deutsche Bank AG 724086 2.43% -395093 -35.30% 2017-12-31
Tourbillon Capital Partners LP 585000 1.97% 190000 48.10% 2017-12-31
THREE ARCH PARTNERS IV LP 1168321 4.04% 1168321 -- 2016-12-31
Johnson & Johnson 1400824 4.85% -665916 -32.22% 2016-12-31
Citadel Advisors Llc 1032585 3.49% -53224 -4.90% 2017-09-30
Lord, Abbett & Co LLC 744214 2.60% 17397 2.39% 2016-09-30
NEA Management Company, LLC 660428 2.31% -- -- 2016-09-30
1832 Asset Management L.P 614300 2.15% 539300 719.07% 2016-09-30
Wellington Management Company LLP 600611 2.10% 328778 120.95% 2016-09-30
Bay City Capital LLC 700000 2.46% -1517214 -68.43% 2016-08-09
Cormorant Asset Management, LLC 491044 1.72% -- -- 2016-09-30
Oak Ridge Investments, LLC 472940 1.65% -60424 -11.33% 2016-09-30
American Century Inv Mgt Inc 438436 1.53% 195252 80.29% 2016-09-30
Nathan B. Pliam, M.D 2217214 3.00% 108111355 0.10% 1999-11-30
Wilfred E. Jaeger, M.D. 2210569 3.00% 107787344 0.10% 1999-11-30
Novo A/S 2194841 3.00% 107020447 0.10% 1999-11-30
AMV Partners II, L.P. 1685340 3.00% 82177178 0.10% 1999-11-30
Entities affiliated with Aberdare Ventures 1615273 3.00% 78760711 0.10% 1999-11-30
Ali Behbahani, M.D. 1367649 3.00% 66686565 -- 1999-11-30
Johnson Johnson Development Corporation 3077005 3.00% 150034764 0.10% 1999-11-30
共同基金持股
持有者 持有份额 持股比例 份额变化 变化率 报告日期
Alger SMid Cap Focus Fund 270013 0.88% -7383 -2.66% 2019-05-31
Franklin US Opportunities Fund 506313 1.66% -- -- 2019-06-30
Franklin Small Cap Growth Fund 628600 2.06% -- -- 2019-06-30
iShares Russell 2000 ETF 651815 2.14% 8108 1.26% 2019-07-30
T. Rowe Price Health Sciences Fund 703882 2.31% 703882 -- 2019-06-30
Vanguard Small Cap Index 744309 2.44% 28661 4.00% 2019-06-30
Vanguard Total Stock Market Index Fund 780115 2.56% 7863 1.02% 2019-06-30
T. Rowe Price New Horizons Fund 1056800 3.46% 1056800 -- 2019-06-30
Invesco Oppenheimer Global Opports Fund 1500000 4.91% -- -- 2019-06-30
Franklin Growth Opportunities Fund 501908 1.64% -- -- 2019-06-30
Franklin Technology Fund 293800 0.96% -- -- 2019-06-30
iShares Russell 2000 Growth ETF 271150 0.89% 3205 1.20% 2019-07-30
Vanguard Small Cap Growth Index Fund 424807 1.39% 19946 4.93% 2019-06-30
Meridian Small Cap Growth Fund 317790 1.04% -- -- 2019-03-31
JPM Global Healthcare Fund 339220 1.11% -- -- 2019-06-30
Meridian Growth Fund 347345 1.14% -- -- 2019-03-31
T. Rowe Price Small-Cap Stock Fund 380281 1.25% 35294 10.23% 2019-06-30
Vanguard Explorer Fund 407939 1.34% 29855 7.90% 2019-03-31
JPMorgan Small Cap Growth Fund 419940 1.38% 12069 2.96% 2019-06-30
Vanguard Extended Market Index Fund 422044 1.38% 557 0.13% 2019-06-30
CREF Stock Account 246314 0.81% -- -- 2019-04-30
BNY Mellon Sm/Md Cp Gr Fd 251162 0.82% 42749 20.51% 2019-05-31
BlackRock Health Sciences Opps Port 240600 0.79% -- -- 2019-05-31
iShares US Small Cap ETF (CAD-Hedged) 593785 1.95% -999 -0.17% 2019-05-30
Vanguard Small Cap Index Fund 714655 2.34% 5580 0.79% 2019-04-30
Oppenheimer Global Opportunities Fund 1500000 4.91% -- -- 2019-03-31
Federated Kaufmann Fund 360294 1.18% -- -- 2018-12-31
SPDR 230952 0.76% 1511 0.66% 2019-04-26
SEB Life Intl E-Fund 293800 0.97% -- -- 2019-02-28
Dreyfus/The Boston Co Sm/Md Cp Gr Fd 246016 0.81% 8527 3.59% 2019-01-31
iShares US Medical Devices ETF 309063 1.02% 1058 0.34% 2019-02-28
ILI Franklin US Opportunities EUR 548618 1.81% -- -- 2019-02-28
PGIM Jennison Health Sciences Fund 300385 0.99% -- -- 2019-01-31
JPM Global Healthcare Fund UL 339220 1.12% 7348 2.21% 2019-01-31
ZI Franklin US Opportunities 548618 1.81% 67787 14.10% 2019-01-31
FPIL Optus JF Glb Life Sciences Theme 339220 1.12% 7348 2.21% 2019-01-31
Buffalo Discovery Fund 247415 0.81% -101600 -29.11% 2018-09-30
Worldwide Healthcare 389500 1.29% -53700 -12.12% 2018-10-31
Janus Henderson Triton Fund 686722 2.28% -265042 -27.85% 2018-09-30
Lord Abbett Developing Growth Fund 295037 0.98% 46590 18.75% 2018-04-30
Wells Fargo Discovery Fund 300100 1.00% -- -- 2018-06-30
AZ InvestEd Ivy Small Cap Growth Fund 346837 1.15% 31100 9.85% 2018-06-30
Wells Fargo Growth Fund 394163 1.31% 41600 11.80% 2018-06-30
PGIM Jennison Small Company Fund 396684 1.32% -- -- 2018-10-31
Goldman Sachs Small/Mid Cap Growth Fund 345922 1.15% -- -- 2018-06-30
Goldman Sachs Small/Mid Cap Growth A 345922 1.15% -- -- 2018-06-30
AZ InvestEd Ivy Small Cap Growth E 346837 1.15% 31100 9.85% 2018-06-30
Buffalo Discovery 349015 1.16% -64800 -15.66% 2018-06-30
Prudential Jennison Health Sciences A 536744 1.78% 9536 1.81% 2018-07-31
Franklin Small Cap Growth A 582700 1.93% 49900 9.37% 2018-07-31
Vanguard Total Stock Mkt Idx 675091 2.24% 828 0.12% 2018-07-31
Oppenheimer Global Opportunities A 900000 2.99% -- -- 2018-07-31
Janus Triton D 951764 3.16% -- -- 2018-06-30
BlackRock Health Sciences Opps Inv A 451200 1.50% -- -- 2018-07-31
Janus Global Life Sciences D 345562 1.15% -62654 -15.35% 2018-06-30
Prudential Jennison Small Company B 396684 1.32% -107021 -21.25% 2018-07-31
JPMorgan Small Cap Growth A 302707 1.01% 22798 8.14% 2018-07-31
Vanguard Explorer Inv 213671 0.71% 32498 17.94% 2018-06-30
Federated Kaufmann R 215000 0.71% -25000 -10.42% 2018-06-30
iShares Russell 2000 Growth 280059 0.86% -270 -0.10% 2018-09-12
Artisan Small Cap Investor 249538 0.83% 8687 3.61% 2018-06-30
Vanguard Extended Market Idx Inv 372284 1.24% 3000 0.81% 2018-07-31
Franklin Growth Opportunities A 384397 1.28% 60656 18.74% 2018-07-31
Vanguard Small Cap Growth Index Inv 388350 1.29% 5342 1.39% 2018-07-31
Wells Fargo Discovery Admin 300100 1.00% -- -- 2018-06-30
Wells Fargo Growth A 394163 1.31% 41600 11.80% 2018-06-30
Wells Fargo Small Company Growth Admin 267637 0.89% 15556 6.17% 2018-06-30
Fidelity 550000 1.83% 50000 10.00% 2018-06-30
RI CBF AllianceBern Discovery Gr RA 268842 0.89% -23500 -8.04% 2018-06-30
Goldman Sachs Growth Opportunities A 254199 0.85% -26030 -9.29% 2018-03-31
Lord Abbett Developing Growth A 295037 0.98% 46590 18.75% 2018-04-30
AB Small Cap Growth A 208445 0.70% -310 -0.15% 2018-02-28
Invesco Small Cap Growth A 210931 0.71% 326 0.15% 2017-09-30
Franklin Small-Mid Cap Growth A 221500 0.75% -- -- 2017-09-30
American Century Heritage Inv 433118 1.51% 130152 42.96% 2016-12-31
Buffalo Small Cap 222863 0.78% -71150 -24.20% 2016-09-30
Oak Ridge Small Cap Growth A 285000 0.99% -65000 -18.57% 2016-11-30
RI CBF AllianceBern Discovery Growth 515896 2.10% 89691 21.00% 2015-08-31
Fidelity® Select Medical Equip & Systems 440000 1.80% 100000 29.40% 2015-08-31
Buffalo Small Cap Fund 434390 1.70% 434390 -- 2015-06-30
Franklin Small-Mid Cap Growth Fund 399100 1.60% 231100 137.60% 2015-09-30
JPM Global Healthcare 382329 1.50% -- -- 2015-08-31
Fidelity Advisor® Health Care Fund 309700 1.20% 172200 125.20% 2015-08-31
AB Small Cap Growth Portfolio 287289 1.10% 28711 11.10% 2015-08-31
Oak Ridge Small Cap Growth Fund 263556 1.10% 263556 -- 2015-05-31
iShares Russell 2000 (AU) 253976 0.90% 3685 1.50% 2015-10-30
Fidelity® Select Health Care Portfolio 1000000 4.00% 500000 100.00% 2015-08-31
MLIS CCI Healthcare L/S Ucits 221604 0.90% 221604 -- 2015-03-31

Michael F. DeMane Michael F. DeMane is on the board of Rotation Medical, Inc., Nevro Corp. (former Chairman), Safe Orthopaedics SAS and Cardionomic, Inc. In his past career Mr. DeMane occupied the position of Managing Director at Smith & Nephew Pty Ltd.(Australia), Managing Director at Smith & Nephew Pty Ltd. (New Zealand), Chairman & Chief Executive Officer for Lanx, Inc., Chief Operating Officer of Medtronic, Inc., President-Orthopedic Implant Division at Smith & Nephew Orthopaedics Ltd. and Director & President-Interbody Technologies at Medtronic Sofamor Danek, Inc. Mr. DeMane received a graduate degree from Clemson University and an undergraduate degree from St. Lawrence University.
Wilfred E. Jaeger Wilfred E. Jaeger founded Three Arch Partners. Dr. Jaeger is Partner at this company and Managing Member at Three Arch Management IV LLC and Managing Member at Three Arch Management III LLC (both are subsidiaries of Three Arch Partners). Dr. Jaeger is also Managing Member at Three Arch Management IV LLC and on the board of 5 other companies. He previously occupied the position of Chief Executive Officer of Molecular Templates, Inc. and Chief Executive Officer & Director at Threshold Pharmaceuticals, Inc. (a subsidiary of Molecular Templates, Inc.), Principal at Chec Medical Centers, Inc., Principal at Phoenix Partners (Washington), General Partner of Schroder Ventures Fund and General Partner at SV Health Investors LLC. He received an undergraduate degree from the University of British Columbia, an MBA from Stanford Graduate School of Business and a doctorate from the University of British Columbia Faculty of Medicine.
D. Keith Grossman Currently, D. Keith Grossman holds the position of Chairman, President & Chief Executive Officer at Nevro Corp. and Chairman at Outset Medical, Inc. Mr. Grossman is also on the board of Alcon, Inc., Tandem Diabetes Care, Inc., ViewRay, Inc. and Vyaire Holding Co. In his past career he held the position of Head-Sales & Marketing at McGaw Laboratories, Vice President-Sales & Marketing at Calcitek, Inc., President & Chief Executive Officer of Thoratec Corp., President, Chief Executive Officer & Director at Conceptus, Inc., Division President at MAJOR Pharmaceuticals, Inc., Managing Director at TPG Capital LP and Managing Director at TPG Capital LLC. D. Keith Grossman received an undergraduate degree from The Ohio State University and an MBA from Pepperdine Graziadio Business School.
Elizabeth H. Weatherman Elizabeth H. Weatherman is on the board of Vapotherm, Inc. and 12 other companies. In the past she held the position of General Partner of Warburg Pincus & Company US LLC and Managing Director at Warburg Pincus LLC (a subsidiary of Warburg Pincus & Company US LLC). Ms. Weatherman received an MBA from Stanford Graduate School of Business and an undergraduate degree from Mount Holyoke College.
Kevin C. O'Boyle Kevin C. O'Boyle is on the board of GenMark Diagnostics, Inc. and 4 other companies. He previously was Chief Financial Officer & Senior Vice President of NuVasive, Inc., Chief Financial Officer & Senior VP-Operations at Clarient, Inc., Chief Financial Officer & Senior VP-Operations at Albert Fisher North America, Inc., Chief Financial Officer & Senior Vice President of Shire Regenerative Medicine, Inc. and Vice President & Controller for American Cablesystems Corp. Kevin C. O'Boyle received an undergraduate degree from Rochester Institute of Technology.
Frank M. Fischer Mr. Frank M. Fischer is an Independent Director at Nevro Corp., a Chairman & President at NeuroPace, Inc. and a Chairman at TherOx, Inc. He is on the Board of Directors at Nevro Corp., Angel Medical Systems, Inc., Epilepsy Foundation, Proteus Digital Health, Inc. and Babson College. Mr. Fischer was previously employed as a President, Chief Executive Officer & Director by Heartport, Inc., a President, Chief Executive Officer & Director by Ventritex, Inc., an Advisor by Aphelion Capital LLC, a President-Implantable Products Division by Cordis Corp., a Chairman by eNeura, Inc., and a Principal by General Electric Co. He also served on the board at Autonomic Technologies, Inc. and Leptos Biomedical, Inc. He received his graduate degree from Rensselaer Polytechnic Institute.
Brad H. Vale Brad H. Vale is on the board of Agilvax, Inc. and Nevro Corp. In his past career Dr. Vale occupied the position of Director at Synecor LLC, Principal at BioRexis Pharmaceutical Corp., Principal at SGX Pharmaceuticals, Inc., Principal at Ethicon, Inc. and Vice President for Johnson & Johnson Innovation JJDC, Inc. He received a doctorate from Iowa State University, a doctorate from Washington State University and an undergraduate degree from Beloit College.
Bradford E. Gliner Founder of Heartstream, Inc., Bradford E. Gliner presently is Vice President-Clinical & Regulatory Affairs at Nevro Corp. In the past he held the position of President & Chief Executive Officer of Mitoguard Neuroscience, Inc. and Vice President-Research at Northstar Neuroscience, Inc. Mr. Gliner received an undergraduate degree from the University of Illinois and a graduate degree from The Johns Hopkins University.
Juliet Cunningham Currently, Juliet Cunningham holds the position of Vice President-Investor Relations for Nevro Corp. and Vice President-Investor Relations for Alere, Inc. In the past Ms. Cunningham held the position of Senior Vice President-Corporate Communications at Lytx, Inc., VP-Investor Relations & Corporate Communications at Mitek Systems, Inc., Managing Director at The Blueshirt Group LLC, Vice President-Investor Relations & Communications at Novatel Wireless, Inc. and Director-Public Relations & Communications at Staccato Communications, Inc. Juliet Cunningham received an undergraduate degree from the University of Phoenix.
Lori M. Ciano Currently, Lori M. Ciano occupies the position of Chief Human Resources Officer for Nevro Corp. In her past career Ms. Ciano was Senior Vice President-Human Resources at Dermira, Inc., Chief Human Resources Officer & Vice President at Thoratec Corp., Senior Director-Human Resources at Novellus Systems, Inc., Executive Vice President-Human Resources for Conceptus, Inc. and Senior Vice President-Human Resources at Affymetrix, Inc. Lori M. Ciano received an MBA from Santa Clara University, an undergraduate degree from San Jose State University and a graduate degree from John F. Kennedy University.
Ali Behbahani Currently, Ali Behbahani is General Partner at NEA Management Co. LLC. He is also on the board of 14 other companies. In his past career Dr. Behbahani was Consultant at The Medicines Co., Venture Associate at Morgan Stanley and Analyst at Lehman Brothers Asset Management LLC. Dr. Behbahani received an undergraduate degree from Duke University, an MBA from The Wharton School of the University of Pennsylvania and a doctorate from Perelman School of Medicine.
Lisa D. Earnhardt Presently, Lisa D. Earnhardt is President, Chief Executive Officer & Director at Intersect ENT, Inc. Ms. Earnhardt is also on the board of Advanced Medical Technology Association and Nevro Corp. and Member of Young Presidents' Organization, Inc. In the past Lisa D. Earnhardt was President-Cardiac Surgery Division at Boston Scientific Corp. and Vice President-Sales & Marketing for Guidant Corp. (a subsidiary of Boston Scientific Corp.) and Director-Kellogg Alumni Council at Kellogg School of Management. She received an undergraduate degree from Stanford University and an MBA from Kellogg School of Management.
Andrew Hugh Galligan Currently, Andrew Hugh Galligan holds the position of Chief Financial Officer for Nevro Corp. He is also on the board of Ooma, Inc. and Nevro Medical Ltd. and Fellow at The Institute of Chartered Accountants in Ireland. In his past career he held the position of Chief Financial Officer for Corcept Therapeutics, Inc., Chief Financial Officer for Ooma, Inc., Chief Financial Officer for Lumisys, Inc., Chief Financial Officer for Metrika, Inc., Chief Financial Officer at Amira Medical, Inc., Chief Financial Officer & Vice President-Finance at Reliant Technologies, Inc., Chief Financial Officer of IPS Health Care, Inc. and Chief Financial Officer for Molecular Devices LLC. Andrew Hugh Galligan received an undergraduate degree from Trinity College Dublin.
Bradford E. Gliner Founder of Heartstream, Inc., Bradford E. Gliner presently is Vice President-Clinical & Regulatory Affairs at Nevro Corp. In the past he held the position of President & Chief Executive Officer of Mitoguard Neuroscience, Inc. and Vice President-Research at Northstar Neuroscience, Inc. Mr. Gliner received an undergraduate degree from the University of Illinois and a graduate degree from The Johns Hopkins University.
Shawn T. McCormick Shawn T. McCormick is on the board of SurModics, Inc., Nevro Corp. and Inspire Medical Systems, Inc. In his past career he held the position of Chief Financial Officer at Wright Medical Group NV Chief Financial Officer & Head-Media Relations at Tornier NV and Chief Financial & Accounting Officer for Tornier, Inc. (both are subsidiaries of Wright Medical Group NV), Chief Operating Officer for Lutonix, Inc., Chief Financial Officer & Senior Vice President of ev3, Inc., Vice President-Corporate Development at Medtronic, Inc. and Auditor of KPMG Peat Marwick LLP. Shawn T. McCormick received an undergraduate degree from Arizona State University and an MBA from The Curtis L. Carlson School of Management.
Niamh Louise Pellegrini Niamh Louise Pellegrini is Chief Commercial Officer at Nevro Corp. In her past career Ms. Pellegrini occupied the position of President, Chief Executive Officer & Director at Autonomic Technologies, Inc., Principal at Lifescan, Inc., Principal at Johnson & Johnson and Vice President at Johnson & Johnson Innovation JJDC, Inc. (a subsidiary of Johnson & Johnson) and President-North American Operations at Thoratec Corp. Niamh Louise Pellegrini received an undergraduate degree and an MBA from Santa Clara University.
Doug Alleavitch Doug Alleavitch is Vice President-Quality at Nevro Corp. Mr. Alleavitch previously occupied the position of Vice President-Operations & Quality Assurance at AEGEA Medical, Inc., Operations Director of Boston Scientific Corp. and Vice President-Manufacturing at AngioScore, Inc. Mr. Alleavitch received an undergraduate degree from Cornell University, a graduate degree and an MBA from the University of Illinois and a graduate degree from Illinois Institute of Technology.
Andrew Hugh Galligan Currently, Andrew Hugh Galligan holds the position of Chief Financial Officer for Nevro Corp. He is also on the board of Ooma, Inc. and Nevro Medical Ltd. and Fellow at The Institute of Chartered Accountants in Ireland. In his past career he held the position of Chief Financial Officer for Corcept Therapeutics, Inc., Chief Financial Officer for Ooma, Inc., Chief Financial Officer for Lumisys, Inc., Chief Financial Officer for Metrika, Inc., Chief Financial Officer at Amira Medical, Inc., Chief Financial Officer & Vice President-Finance at Reliant Technologies, Inc., Chief Financial Officer of IPS Health Care, Inc. and Chief Financial Officer for Molecular Devices LLC. Andrew Hugh Galligan received an undergraduate degree from Trinity College Dublin.
Richard B. Carter Currently, Richard B. Carter holds the position of Vice President-Finance & Controller at Nevro Corp. In the past Mr. Carter occupied the position of Vice President-Finance & Controller at MiaSol�0�1�0�8, Inc., Vice President-Finance & Controller at Kovio, Inc., Corporate Controller at Doosan Fuel Cell America, Inc., Auditor for Ernst & Young LLP, Corporate Controller at PortalPlayer, Inc. and Corporate Controller at Transmeta Corp. Richard B. Carter received an undergraduate degree from The California State University.
Divyasmita Ghatak Divyasmita Ghatak holds the position of Vice President-Human Resources for Nevro Corp. She is also on the board of Watermark (United States). She previously was Principal at Cisco Systems, Inc., Director-Human Resources at Tavant Technologies, Inc. and Chief People Officer at GoodData Corp. She received an undergraduate degree from the University of Delhi and a graduate degree from Tata Institute of Social Sciences.
David Caraway David Caraway holds the position of Chief Medical Officer of Nevro Corp. In the past he was Chief Executive Officer of Tristate LLC and Chief Executive Officer for Center For Pain Relief. Dr. Caraway received an undergraduate degree from the University of Virginia, a doctorate from The University of Virginia School of Medicine and a doctorate from The College & Graduate School of Arts & Sciences.
Doug Alleavitch Doug Alleavitch is Vice President-Quality at Nevro Corp. Mr. Alleavitch previously occupied the position of Vice President-Operations & Quality Assurance at AEGEA Medical, Inc., Operations Director of Boston Scientific Corp. and Vice President-Manufacturing at AngioScore, Inc. Mr. Alleavitch received an undergraduate degree from Cornell University, a graduate degree and an MBA from the University of Illinois and a graduate degree from Illinois Institute of Technology.
Katherine Bock Presently, Katherine Bock holds the position of Manager-Investor Relations for Nevro Corp. Ms. Bock is also VP-Investor Relations & Corporate Communications at Adverum Biotechnologies, Inc.
Christopher Christoforou Presently, Christopher Christoforou occupies the position of Vice President-Research & Development of Nevro Corp. In his past career Mr. Christoforou was Vice President-Quality Engineering at Thoratec Corp. and Manager-Engineering at United States Surgical Corp. He received an undergraduate degree from Boston University and a graduate degree from The Johns Hopkins University.
Neeraj Teotia Neeraj Teotia is Vice President-Marketing at Nevro Corp. In the past he held the position of Director-New Business Development at Johnson & Johnson. He received an MBA from Kellogg School of Management and an undergraduate degree from the University of Illinois.
Patrick Schmitz Patrick Schmitz occupies the position of Vice President-Operations of Nevro Corp. In the past he was Vice President-Operations for Thoratec Corp. and Vice President-North American Operations at GN Hearing Care Corp. He received an undergraduate degree from the University of Wisconsin-Stout.
Divyasmita Ghatak Divyasmita Ghatak holds the position of Vice President-Human Resources for Nevro Corp. She is also on the board of Watermark (United States). She previously was Principal at Cisco Systems, Inc., Director-Human Resources at Tavant Technologies, Inc. and Chief People Officer at GoodData Corp. She received an undergraduate degree from the University of Delhi and a graduate degree from Tata Institute of Social Sciences.
Kashif Rashid Kashif Rashid occupies the position of Secretary & Chief Compliance Officer of Nevro Corp. Mr. Rashid is also on the board of Nevro Medical Ltd. In his past career Mr. Rashid held the position of Vice President-Legal at Atara Biotherapeutics, Inc. and Deputy General Counsel & Associate General Counsel at St. Jude Medical, Inc. (Texas). He received an undergraduate degree from George Washington University and a graduate degree from Georgetown University Law Center.
Michael Carter Michael Carter holds the position of Vice President-Global Sales of Nevro Corp. Mr. Carter received an undergraduate degree from US Military Academy.

量化对比

全部评论 0

  • 暂无评论

阿布量化公众号二维码 abu_quant 扫一扫关注阿布量化

热门推荐